pagli Film Starring Feminist Provocateur Camille Paglia and Drag Queen Glennda Orgasm to Screen at the National Gallery of Art in Washington DC, June 24 By www.24-7pressrelease.com Published On :: Mon, 22 May 2023 08:00:00 GMT The NGA celebrates the 30th anniversary of "Glennda and Camille Do Downtown" plus other works from the Glenn Belverio Archive. Full Article
pagli Magic The Gathering: Amazing Character Concept Artworks of Filipe Pagliuso By designyoutrust.com Published On :: Sat, 09 Nov 2024 12:15:35 +0000 Filipe Pagliuso is a Brazilian digital artist known for his captivating character designs and fantasy illustrations. He graduated in Graphic Design from UNESP and has a strong foundation in digital art techniques. He has contributed to the Magic: The Gathering (MTG) universe, creating artwork for several cards. Notable examples include “Kibo, Uktabi Prince” from Jumpstart […] Full Article Inspirations amazing brazilian character creating design designs examples graphic illustrations magic
pagli Littler’s Michael Paglialonga Testifies Before New York City Council on Safe Hotels Act Flaws By www.littler.com Published On :: Wed, 09 Oct 2024 17:49:17 +0000 NEW YORK (October 9, 2024) – Littler attorney Michael Paglialonga testified before the New York City Council’s Committee on Consumer and Worker Protection today on behalf of Littler’s Workplace Policy Institute® (WPI®), the firm’s government relations and public policy arm. Full Article
pagli The Zach Bryan and Brianna LaPaglia Split Gets Even Messier By www.vulture.com Published On :: Tue, 12 Nov 2024 20:00:00 GMT Here’s everything you need to know about the allegations, diss tracks, and that $12 million NDA. Full Article zach bryan brianna chickenfry brianna lapaglia news celebrity breakups celebrity relations breakups statements barstool sports explainers vulture homepage lede
pagli Heart Attack Patients Benefit from SGLT2 Inhibitor Empagliflozin By www.medindia.net Published On :: In patients hospitalized for medlinkacute myocardial infarction/medlink (MI), the SGLT2 inhibitor empagliflozin offers significant kidney protection. Full Article
pagli MASCAGNI, P.: Cavalleria rusticana / LEONCAVALLO, R.: Pagliacci [Operas] (Di Toro, Iversen, Graz Opera Chorus, Graz Philharmonic, Lyniv) (OC987) By www.naxos.com Published On :: Sat, 01 Feb 2020 00:00:00 GMT Full Article
pagli LEONCAVALLO, R.: Pagliacci [Opera] (Sepe, Villari, Cecconi, Fiorentino Maggio Musicale Chorus and Orchestra, Galli) (CDS7863) By www.naxos.com Published On :: Sat, 01 Feb 2020 00:00:00 GMT Full Article
pagli LEONCAVALLO, R.: Pagliacci [Opera] (Maggio Musicale Fiorentino, 2019) (NTSC) (DYN-37863) By www.naxos.com Published On :: Sat, 01 Feb 2020 00:00:00 GMT Full Article
pagli LEONCAVALLO, R.: Pagliacci [Opera] (Maggio Musicale Fiorentino, 2019) (Blu-ray, HD) (DYN-57863) By www.naxos.com Published On :: Sat, 01 Feb 2020 00:00:00 GMT Full Article
pagli Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Induced Obese Mice By diabetes.diabetesjournals.org Published On :: 2020-04-24T18:07:35-07:00 Sodium glucose co-transporter-2 inhibitors (SGLT2i) have favorable cardiovascular outcomes in diabetic patients. However, whether SGLT2i can improve obesity-related cardiac dysfunction is unknown. Sestrin2 is a novel stress-inducible protein that regulates AMPK-mTOR and suppresses oxidative damage. The aim of this study was to determine whether empagliflozin (EMPA) improves obesity-related cardiac dysfunction via regulating Sestrin2-mediated pathways in diet-induced obesity. C57BL/6J mice and Sestrin2 knockout mice were fed a high-fat diet (HFD) for 12 weeks and then treated with or without EMPA (10 mg/kg) for 8 weeks. Treating HFD-fed C57BL/6J mice with EMPA reduced body weight, whole-body fat, and improved metabolic disorders. Furthermore, EMPA improved myocardial hypertrophy/fibrosis and cardiac function, and reduced cardiac fat accumulation and mitochondria injury. Additionally, EMPA significantly augmented Sestrin2 levels, increased AMPK and eNOS phosphorylation, but inhibited Akt and mTOR phosphorylation. These beneficial effects were partially attenuated in HFD-fed Sestrin2 knockout mice. Intriguingly, EMPA treatment enhanced the Nrf2/HO-1-mediated oxidative stress response, suggesting antioxidant and anti-inflammatory activity. Thus, EMPA improved obesity-related cardiac dysfunction via regulating Sestrin2-mediated AMPK-mTOR signaling and maintaining redox homeostasis. These findings provide a novel mechanism for the cardiovascular protection of SGLT2i in obesity. Full Article
pagli Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes By care.diabetesjournals.org Published On :: 2013-10-01 Ralph A. DeFronzoOct 1, 2013; 36:3169-3176Emerging Technologies and Therapeutics Full Article
pagli Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study By care.diabetesjournals.org Published On :: 2015-03-01 Robert R. HenryMar 1, 2015; 38:412-419Evolving Tactics With Inhibition of Sodium-Glucose Cotransporters Full Article
pagli Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial By care.diabetesjournals.org Published On :: 2014-06-01 Hans-Ulrich HäringJun 1, 2014; 37:1650-1659Emerging Technologies and Therapeutics Full Article
pagli Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial By care.diabetesjournals.org Published On :: 2019-12-01 Helena W. RodbardDec 1, 2019; 42:2272-2281Emerging Therapies: Drugs and Regimens Full Article
pagli Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial By care.diabetesjournals.org Published On :: 2020-04-03T07:56:03-07:00 OBJECTIVETo determine the effects of dapagliflozin in patients with heart failure (HF) and type 2 diabetes mellitus (T2DM) on left ventricular (LV) remodeling using cardiac MRI.RESEARCH DESIGN AND METHODSWe randomized 56 patients with T2DM and HF with LV systolic dysfunction to dapagliflozin 10 mg daily or placebo for 1 year, on top of usual therapy. The primary end point was difference in LV end-systolic volume (LVESV) using cardiac MRI. Key secondary end points included other measures of LV remodeling and clinical and biochemical parameters.RESULTSIn our cohort, dapagliflozin had no effect on LVESV or any other parameter of LV remodeling. However, it reduced diastolic blood pressure and loop diuretic requirements while increasing hemoglobin, hematocrit, and ketone bodies. There was a trend toward lower weight.CONCLUSIONSWe were unable to determine with certainty whether dapagliflozin in patients with T2DM and HF had any effect on LV remodeling. Whether the benefits of dapagliflozin in HF are due to remodeling or other mechanisms remains unknown. Full Article
pagli Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study By care.diabetesjournals.org Published On :: 2020-01-20T12:00:30-08:00 OBJECTIVE Data regarding the effects of sodium–glucose cotransporter 2 inhibitors in the elderly (age ≥65 years) and very elderly (age ≥75 years) are limited. RESEARCH DESIGN AND METHODS The Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 assessed cardiac and renal outcomes of dapagliflozin versus placebo in patients with type 2 diabetes. Efficacy and safety outcomes were studied within age subgroups for treatment effect and age-based treatment interaction. RESULTS Of the 17,160 patients, 9,253 were <65 years of age, 6,811 ≥65 to <75 years, and 1,096 ≥75 years. Dapagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure consistently, with a hazard ratio (HR) of 0.88 (95% CI 0.72, 1.07), 0.77 (0.63, 0.94), and 0.94 (0.65, 1.36) in age-groups <65, ≥65 to <75, and ≥75 years, respectively (interaction P value 0.5277). Overall, dapagliflozin did not significantly decrease the rates of major adverse cardiovascular events, with HR 0.93 (95% CI 0.81, 1.08), 0.97 (0.83, 1.13), and 0.84 (0.61, 1.15) in age-groups <65, ≥65 to <75, and ≥75 years, respectively (interaction P value 0.7352). The relative risk reduction for the secondary prespecified cardiorenal composite outcome ranged from 18% to 28% in the different age-groups with no heterogeneity. Major hypoglycemia was less frequent with dapagliflozin versus placebo, with HR 0.97 (95% CI 0.58, 1.64), 0.50 (0.29, 0.84), and 0.68 (0.29, 1.57) in age-groups <65, ≥65 to <75, and ≥75 years, respectively (interaction P value 0.2107). Safety outcomes, including fractures, volume depletion, cancer, urinary tract infections, and amputations were balanced with dapagliflozin versus placebo, and acute kidney injury was reduced, all regardless of age. Genital infections that were serious or led to discontinuation of the study drug and diabetic ketoacidosis were uncommon, yet more frequent with dapagliflozin versus placebo, without heterogeneity (interaction P values 0.1058 and 0.8433, respectively). CONCLUSIONS The overall efficacy and safety of dapagliflozin are consistent regardless of age. Full Article
pagli Jonathan LaPaglia feared Zika virus while filming Survivor By www.dailymail.co.uk Published On :: Sat, 29 Jul 2017 15:33:06 GMT With Australian Survivor set to return on Sunday, host Jonathan LaPaglia revealed he thought he had contracted the Zika virus while filming the reality show Full Article
pagli Rebecca Judd recalls the awkward moment Survivor host Jonathan LaPaglia thought she was flirting By www.dailymail.co.uk Published On :: Tue, 06 Aug 2019 08:17:46 GMT Rebecca Judd, 36, has recalled her very awkward run-in with Australian Survivor host, Jonathan LaPaglia, 49. Full Article
